Scrip
NME postmarketing safety reviews are labour-intensive, US FDA finds
16 October 2009
Sue Sutter
A US
FDA pilot programme that reviewed the postmarketing safety of five new molecular entities (NMEs) identified a total of 22 safety issues for follow-up, consumed more than 1,000 staff hours and showed no strong correlation between the time needed to conduct the analyses and the extent of a drug's...
Please Login to read the full article.
16 October 2009
Sue Sutter
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
- FDA advisors back limited expansion of Cymbalta's pain indications
- 2009 results preview: big pharma grapples to varying degrees of success with generic erosion
- NeurogesX to market Qutenza for PHN on its own
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
